News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY) Seeks Approvals for New Skin Cancer Drug


5/11/2011 7:03:09 AM

Roche (ROG.VX) is seeking European and U.S. backing for vemurafenib, a drug to treat the deadliest form of skin cancer, the Swiss drugmaker said on Wednesday.

Analysts have estimated the drug, which Roche wants to use to treat patients with BRAF V600 mutation-positive metastatic melanoma, will have peak sales of 500 million to 1 billion Swiss francs ($0.5-1 billion).

Sentiment towards Roche is starting to improve thanks to a string of more positive product developments this year, helping to boost investors' confidence after they were rattled by development setbacks last year.



comments powered by Disqus
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES